In the Netherlands, a collaboration of (pediatric) nephrologists nationwide led to a new treatment guideline which in the end enables tailored therapy with the orphan drug eculizumab and a considerable cost reduction. The nationwide study CUREiHUS, initiated by the Radboudumc and led by Dr Nicole van de Kar, pediatric nephrologist, Prof Jack Wetzels, nephrologist and Kioa Wijnsma, PhD candidate, is one of the hallmarks of this new national approach and acquires a lot of (inter)national attention.Eculizumab, nowadays the standard treatment for patients with atypical hemolytic uremic syndrome (aHUS), is considered one of world’s most expensive drugs with costs as high as €500,000 per patient per year. Besides the high price tag of eculizumab, physicians treating aHUS patients have sincere concerns regarding the long term consequences, when eculizumab is used as lifelong maintenance therapy. Especially since there is little to no evidence to support this life long duration. In the Netherlands, this led to the development of a new Dutch guideline, drafted by the National Working Group aHUS, which enables a restrictive eculizumab regimen. The implementation of this guideline led to a whole new political discussion in the Netherlands. Only recently, the National Health Care Institute of the Netherlands declined reimbursement of eculizumab as lifelong therapy. However, with the implementation of this new guideline, which is shown to be (cost) effective and safe, the minister of Health has decided to reimburse eculizumab reimbursed, solely when subscribed according to the new guideline. Instead of lifelong maintenance therapy with the orphan drug eculizumab, patients will receive eculizumab for three months after which therapy will be evaluated and while closely monitored withdrawn if possible. With this nationwide prospective study, abbreviated CUREiHUS (NTR5988), sponsored by ZonMw and Zorgverzekeraars Nederland, this restrictive regimen will be monitored for and evaluated after four years.
Recently the newspaper NRC published a extensive background story regarding this new and unique phenomenon in the Netherlands, interviewing both involved patients as physicians and politicians.
See also: link.
Related news items
Online intervention for women exposed to intimate partner violence21 November 2019
Within the SAFE project from the department of Primary and Community Care an eHealth intervention has been developed for women exposed to intimate partner violence (IPV).read more
A personal touch of Sander Leeuwenburgh21 November 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Sander Leeuwenburgh.read more
Technology for Oncology II grant application funded21 November 2019
The grant application called "aiREAD – Accurate and Intelligent Reading for EArlier breast cancer Detection” by project leader Ioannis Sechopoulos, has been selected for funding under the NWO TTW – KWF Kankerbestrijding – Top Sector LSH Partnership “Technology for Oncology II”.read more
KNCV Golden Master Award call for nominations20 November 2019
The Royal Netherlands Chemistry Society awards this prize each year to the best Master’s research project. The Master’s thesis must relate to research in the field of chemistry, life sciences, process technology or (bio-)molecular sciences. Deadline: 31-12-2019.read more
Podosome nanoscale architecture redefined20 November 2019
Koen van den Dries and Alessandra Cambi, theme Nanomedicine, revealed how the nanoscale architecture of podosomes enables dendritic cells to protrude and sense their extracellular environment. They have published their results in Nature Communications.read more
270 times Homo Universalis in Nijmegen20 November 2019
What does a scientist of the future look like? International young scientists addressed this important topic during the ENABLE conference, organized by young researchers for young researchers. They showed how the new generation of researchers wants to open up science to the public.read more